Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis

To Determine the Safety and Efficacy of Oral Rivaroxaban and Standard Anticoagulant in the Treatment of Cerebrosinovenous Thrombosis in Children

The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard anticoagulant in the treatment of cerebrosinovenous thrombosis (CSVT).

There have not been any randomized controlled trials in the country to demonstrate the efficacy, safety and outcome after the oral use of rivaroxaban in pediatric population and establish its protocol with body weight adjusted dosages in children. The findings of this study would not only add to the local data but also be of great interest to physicians and CSVT patients if an anticoagulant were found to have predictable effects and no need for therapeutic INR monitoring.

Inclusion Criteria:

• Any gender
• Aged 2 months to 18 years
• Patients presenting with CSVT evident by computed tomography (CT) or magnetic resonance venography (MRV).

Exclusion Criteria:

• Patients having active bleeding or having high risk of bleeding
• Estimated glomerular filtration rate < 30 milliliter/minute per 1.73 m2.